Patents by Inventor Pablo Umana

Pablo Umana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Trimeric antigen binding molecules
    Patent number: 9975958
    Abstract: The present invention pertains to a trimeric antigen binding molecule comprising three fusion polypeptides, each comprising at least one antigen binding moiety fused to a trimerization domain derived from human cartilage matrix protein. In addition, the present invention relates to polynucleotides encoding such trimeric antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the trimeric antigen binding molecules of the invention, and to methods of using these trimeric antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: May 22, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Claudia Ferrara Koller, Sandra Grau-Richards, Ekkehard Moessner, Pablo Umana
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE
    Publication number: 20180133315
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD79b antibody-drug conjugate.
    Type: Application
    Filed: November 9, 2017
    Publication date: May 17, 2018
    Applicants: Hoffmann-La Roche Inc., Genentech, Inc.
    Inventors: Christian Klein, Sabine Lang, Pablo Umana, Andrew Polson
  • Method for the selection of antibodies against BCMA
    Patent number: 9963513
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: May 8, 2018
    Assignee: ENGMAB SÀRL
    Inventors: Minh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • ASPGR ANTIBODIES AND USES THEREOF
    Publication number: 20180118833
    Abstract: The present invention generally relates to antibodies specific for asialoglycoprotein receptor (ASGPR) and their use for selectively delivering effector moieties that influence cellular activity. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies of the invention, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: September 21, 2017
    Publication date: May 3, 2018
    Applicant: ROCHE GLYCART AG
    Inventors: Thomas HOFER, Changhua Ji, Ekkehard Moessner, Pablo Umana
  • Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
    Patent number: 9957326
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: May 1, 2018
    Assignee: ROCHE GLYCART AG
    Inventors: Pablo Umaña, Ekkehard Mössner
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20180086849
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: July 20, 2017
    Publication date: March 29, 2018
    Inventors: Marina Bacac, Peter Bruenker, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
  • Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5
    Patent number: 9926379
    Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: March 27, 2018
    Assignee: ROCHE GLYCART AG
    Inventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser
  • ANTI-CEA ANTIBODIES
    Publication number: 20180079827
    Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
    Type: Application
    Filed: June 21, 2017
    Publication date: March 22, 2018
    Applicant: Roche Glycart AG
    Inventors: Thomas U. Hofer, Ralf Hosse, Ekkehard Moessner, Pablo Umana
  • Bispecific T cell activating antigen binding molecules
    Patent number: 9914776
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: March 13, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Jaeger, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • Trivalent, bispecific antibodies
    Patent number: 9890204
    Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: February 13, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Eike Hoffmann, Christian Klein, Ekkehard Moessner, Juergen Michael Schanzer, Claudio Sustmann, Pablo Umana
  • INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOF
    Publication number: 20180009868
    Abstract: The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: September 5, 2017
    Publication date: January 11, 2018
    Applicant: Roche Glycart AG
    Inventors: Ralf Hosse, Christian Klein, Ekkehard Moessner, Laurence Bernard Peterson, Pablo Umana, Linda Wicker
  • METHODS OF TREATING CEA-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-CEA/ANTI-CD3 BISPECIFIC ANTIBODIES
    Publication number: 20180000931
    Abstract: The invention provides compositions and methods for treating CEA-positive cancers. The method comprising administering a PD-1 axis binding antagonist and a bispecific antibody that targets CEA and CD3.
    Type: Application
    Filed: January 5, 2017
    Publication date: January 4, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Sara Colombetti, Christian Klein, Johannes Sam, Jose Saro, Pablo Umana
  • COMBINATION THERAPY OF T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES AND PD-1 AXIS BINDING ANTAGONISTS
    Publication number: 20170349666
    Abstract: The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.
    Type: Application
    Filed: May 19, 2017
    Publication date: December 7, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Vaios Karanikas, Pablo Umana, Alfred Zippelius, Daniela Thommen, Jens Schreiner
  • METHOD FOR THE DETERMINATION OF ANTI-DRUG ANTIBODIES AGAINST AN EFFECTOR FUNCTION SUPPRESSED HUMAN OR HUMANIZED DRUG ANTIBODY
    Publication number: 20170343560
    Abstract: Herein is reported an anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody against an effector function suppressed human or humanized drug antibody in a sample comprising the incubation of a sample comprising mammalian blood serum with full length human Fcgamma receptor I or an Fc-region binding fragment thereof so that a complex between the anti-drug antibody against the effector function suppressed human or humanized drug antibody present in the sample and the human Fcgamma receptor I or the Fc-region binding fragment thereof forms, whereby the full length human Fcgamma receptor I or the Fc-region binding fragment thereof is conjugated to a detectable label, and the determination of the formed complex by the detectable label.
    Type: Application
    Filed: May 5, 2017
    Publication date: November 30, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Pablo Umana, Uwe Wessels, Kay-Gunnar Stubenrauch
  • BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA
    Publication number: 20170327579
    Abstract: A bispecific antibody specifically binding to the extracellular domain of human BCMA and human CD3?, characterized in comprising a common antibody light chain is provided. Such bispecific antibody can be used as a medicament in the treatment of plasma cell disorders like Multiple Myeloma.
    Type: Application
    Filed: November 18, 2015
    Publication date: November 16, 2017
    Inventors: MINH DIEM VU, KLAUS STREIN, OLIVER AST, MARINA BACAC, PETER BRUENKER, TANJA FAUTI, ANNE FREIMOSER-GRUNDSCHOBER, RAFT HOSSE, ADRIAN HUGENMATTER, CHRISTIANE JAEGER, CHRISTIAN KLEIN, EKKEHARD MOESSNER, Samuel MOSER, Pablo UMANA
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD22 ANTIBODY-DRUG CONJUGATE
    Publication number: 20170306040
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD22 antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD22 antibody-drug conjugate.
    Type: Application
    Filed: March 7, 2017
    Publication date: October 26, 2017
    Applicants: Hoffmann-La Roche Inc., Genentech, Inc.
    Inventors: Christian Klein, Sabine Lang, Pablo Umana, Andrew Polson
  • BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND ROR1 FOR USE IN THE TREATMENT OF OVARIAN CANCER
    Publication number: 20170306044
    Abstract: Bispecific antibodies against CD3epsilon and ROR1 are useful for use in the treatmentof ovarian cancer.
    Type: Application
    Filed: October 8, 2015
    Publication date: October 26, 2017
    Inventors: MINH DIEM VU, KLAUS STREIN, OLIVER AST, TANJA FAUTI, ANNE FREIMOSER-GRUNDSCHOBER, RALF HOSSE, CHRISTIAN KLEIN, EKKEHARD MOESSNER, SAMUEL MOSER, RAMONA MURR, PABLO UMANA, SABINE JUNG-IMHOF, STEFAN kLOSTERMANN, MICHAEL MOLHOJ, JOERG REGULA, WOLFGANG SCHAEFER
  • BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND ROR1
    Publication number: 20170306018
    Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.
    Type: Application
    Filed: October 8, 2015
    Publication date: October 26, 2017
    Inventors: MINH DIEM VU, KLAUS STREIN, OLIVER AST, TANJA FAUTI, ANNE FREIMOSER-GRUNDSCHOBER, RALF HOSSE, CHRISTIAN KLEIN, EKKEHARD MOESSNER, SAMUEL MOSER, RAMONA MURR, PABLO UMANA, SABINE JUNG-IMHOF, STEFAN KLOSTERMANN, MICHAEL MOLHOJ, JOERG REGULA, WOLFGANG SCHAEFER
  • BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA
    Publication number: 20170306036
    Abstract: A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3epsilon, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), r aspartic acid (D) (numbering according to Kabat). Also the manufacture and use of said antibody.
    Type: Application
    Filed: August 3, 2015
    Publication date: October 26, 2017
    Applicant: ENGMAB AG
    Inventors: Minh Diem VU, Klaus STREIN, Oliver AST, Marina BACAC, Lydia Jasmin HANISCH, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Samuel MOSER, Ramona MURR, Pablo UMANA, Sabine JUNG-IMHOF, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg REGULA, Wolfgang SCHAEFER
  • ASGPR antibodies and uses thereof
    Patent number: 9771427
    Abstract: The present invention generally relates to antibodies specific for asialoglycoprotein receptor (ASGPR) and their use for selectively delivering effector moieties that influence cellular activity. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies of the invention, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: September 26, 2017
    Assignee: ROCHE GLYCART AG
    Inventors: Thomas Hofer, Changhua Ji, Ekkehard Moessner, Pablo Umana